Novavax Appoints Brian Rosen as Vice President, Government Affairs

March 10, 2015

GAITHERSBURG, Md.March 10, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Brian Rosen to the position of Vice President, Government Affairs and Policy. Mr. Rosen will be responsible for leading government affairs and policy efforts that are instrumental to patient access to Novavax vaccines. Mr. Rosen's efforts will be focused on the company's lead product candidates, including its RSV vaccine franchise, and quadrivalent seasonal and pandemic influenza vaccine candidates.

Mr. Rosen comes to Novavax with over 20 years of industry and patient advocacy experience, the vast majority of which he spent engaged in government affairs, advocacy, reimbursement and policy work. He was most recently the Chief Policy, Advocacy and Patient Access Officer for the Leukemia & Lymphoma Society, where he oversaw all legislative and regulatory efforts and the delivery of patient services nationwide. He previously developed and ran the Government Affairs, Policy and Alliance Development functions for MedImmune, which developed Synagis, a monoclonal antibody used to prevent RSV disease in premature newborns, and FluMist, a live attenuated influenza vaccine.

"The healthcare landscape is constantly changing and supportive vaccine policy requires diligent attention and coordination in concert with Novavax' commercialization plans. Brian's extensive experience, particularly with RSV and influenza, is critical to planning and executing a commercial launch of our vaccines," said John Trizzino, SVP, Commercial Operations. "Brian is a key addition to our management team and brings valuable perspective that I am confident will contribute to bringing our novel vaccines to market."

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for ground-breaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website,

CONTACT: Barclay A. Phillips
         SVP, Chief Financial Officer and Treasurer
         Andrea N. Flynn
         Senior Manager, Investor Relations
         Novavax, Inc.[email protected]